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fter internalization from the plasma membrane,
activated EGF receptors (EGFRs) are delivered to
multivesicular bodies (MVBs). Within MVBs, EGFRs
are removed from the perimeter membrane to internal
vesicles, thereby being sorted from transferrin receptors,
which recycle back to the plasma membrane. The phos-
phatidylinositol (PI) 3
 
 
 
-kinase inhibitor, wortmannin, inhib-
its internal vesicle formation within MVBs and causes
EGFRs to remain in clusters on the perimeter membrane.
Microinjection of isotype-speciﬁc inhibitory antibodies
 
demonstrates that the PI 3
 
 
 
-kinase required for internal
vesicle formation is hVPS34. In the presence of wortmannin,
EGFRs continue to be delivered to lysosomes, showing that
A
 
their removal from the recycling pathway and their delivery
to lysosomes does not depend on inward vesiculation. We
showed previously that tyrosine kinase-negative EGFRs fail
to accumulate on internal vesicles of MVBs but are recycled
rather than delivered to lysosomes. Therefore, we conclude
that selection of EGFRs for inclusion on internal vesicles
requires tyrosine kinase but not PI 3
 
 
 
-kinase activity,
 
whereas vesicle formation requires PI 3
 
 
 
-kinase activity.
Finally, in wortmannin-treated cells there is increased
EGF-stimulated tyrosine phosphorylation when EGFRs are
retained on the perimeter membrane of MVBs. Therefore,
we suggest that inward vesiculation is involved directly
with attenuating signal transduction.
 
Introduction
 
The binding of ligand to growth factor receptors on the cell
surface initiates a series of events including receptor activation,
the activation of target proteins, and endocytosis of the
activated ligand–receptor complex. Both receptor activation
and activation of target proteins begin on the plasma mem-
brane. However, it has been known for some years that receptor
tyrosine kinases remain phosphorylated and are potentially still
active in the endosome (Wada et al., 1992; Futter et al., 1993;
Burke et al., 2001), suggesting that signaling is not attenuated
at the internalization step. Internalized growth factor receptors
may be returned to the plasma membrane and can participate
in further signaling, or they may be delivered to lysosomes and
degraded, resulting in signal attenuation.
Recycling receptors, such as transferrin receptors (TRs)*
and receptors destined for delivery to the lysosome, are
initially internalized into the same endocytic compartment
where they are sorted (Trowbridge et al., 1993; Gruenberg
and Maxfield, 1995; Mellman, 1996). EM shows that
within multivesicular endosomes (multivesicular bodies
[MVBs]) recycling TRs are confined to the perimeter
membrane, and from this location they can return to the
plasma membrane, whereas activated EGF receptors (EGFRs)
accumulate on the internal vesicles of MVBs (Futter and
Hopkins, 1989; Hopkins et al., 1990; Futter et al., 1996).
When all the recycling receptors have been removed, the
MVB fuses directly with the lysosome (van Deurs et al.,
1995; Futter et al., 1996; Mullock et al., 1998), and EGF–
EGFR complexes are rapidly degraded.
The vesiculation processes which give rise to internal
vesicles within MVBs are distinctive because, unlike most
vesiculation processes characterized to date, the vesiculat-
ing membrane buds away from the cytoplasmic matrix.
Unlike coatomer- and clathrin-based mechanisms, the
components regulating this kind of vesiculation are poorly
understood, but in common with these mechanisms they
are likely to require interactions which select and load
cargo and rearrangements within the membrane that lead
to the formation of free vesicles. Our previous data would
suggest that tyrosine kinase activity of the EGFR is required
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for selection of EGFRs for inclusion in the internal vesicle,
since mutant EGFRs lacking tyrosine kinase activity fail to
accumulate on the internal vesicles and are recycled (Felder
et al., 1990). Sequences within the cytoplasmic domain of
the EGFR, distinct from the kinase domain (Kornilova et
al., 1996; Opresko et al., 1995; Kil et al., 1999), and c-Cbl–
Figure 1. The effects of wortmannin on delivery of the EGFR to the lysosome. HEp-2 cells were incubated with HRP for 30 min at 37 C, 
chased for 3 h at 37 C, and then incubated with anti-EGFR gold and EGF for 1 h at 20 C, all in the absence of wortmannin. Cells were then 
chased for 1 h at 37 C in the absence (a) or presence of wortmannin (b and c). Note that in both the absence and the presence of wortmannin, 
the EGFR have, in many cases, reached the HRP-loaded lysosomes (arrows). In the presence of wortmannin, some MVBs (without HRP) are 
enlarged with comparatively few internal vesicles, and EGFRs on the perimeter membrane (asterisks) and some lysosomes (with HRP) are also 
enlarged (crosses). Bar, 0.2  m. 
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mediated ubiquitination of the EGFR (Levkowitz et al.,
1998) are also required for efficient lysosomal targetting of
the receptor, although it is not yet known whether these are
also requirements for sorting within MVBs. However, ubiq-
uitination of carboxypeptidase S was shown recently to be
required for sorting onto internal vesicles of MVBs in yeast
(Katzmann et al., 2001; Reggiori and Pelham, 2001). Given
that tyrosine phosphorylation of c-Cbl by the EGFR kinase
is required for association with and ubiquitination of the
EGFR, c-Cbl phosphorylation may explain at least one re-
quirement for EGFR tyrosine kinase activity in sorting of
EGFRs within the MVB. Additional proteins that may be
involved in sorting within the MVB include annexin 1,
which is phosphorylated by the EGFR kinase on the perime-
ter membrane of the MVB (Futter et al., 1993), Hrs, which
is also a substrate of the EGFR kinase (Komada and Kita-
mura, 1995) and inhibits lysosomal targetting of the EGFR
when overexpressed (Chin et al., 2001; Raiborg et al.,
2001), and sorting nexin (SNX)1, which associates with the
activated EGFR and enhances the efficiency of lysosomal
targeting of the receptor (Kurten et al., 1996). Hrs contains
a domain, which recognizes phosphatidylinositol (PI)(3)P,
and several studies suggest a role for lipids in sorting within
the MVB. Antibodies to lysobisphosphatidic acid (Koba-
yashi et al., 1998) or mutation of the Niemann-Pick type C
gene, which encodes a protein with a sterol-sensing domain,
cause the generation of aberrant MVBs that show defects in
protein and cholesterol sorting (Kobayashi et al., 1999).
Mutations in the yeast PI(3)P 5
 
 
 
-kinase, Fab1, cause defects
in sorting within MVBs (Odorizzi et al., 1998), and in
mammalian melanoma cells treatment with wortmannin
causes the generation of enlarged vacuolar endosomes with a
reduced number of internal vesicles (Fernandez-Borja et al.,
1999), suggesting that the inward vesiculation process is
likely to be regulated by a PI 3
 
 
 
-kinase.
In the current study, we have investigated the role of PI
3
 
 
 
-kinases in sorting within the MVB in HEp-2 cells and
show that the lipid kinase hVPS34 is required for the for-
mation of internal vesicles within the MVB but not for re-
moving activated EGFR from the recycling pathway.
Since we find enhanced tyrosine phosphorylation when
EGFRs are retained on the perimeter membrane of MVBs
in wortmannin-treated cells, we suggest that the incorpo-
ration of activated EGFRs onto the internal vesicles of
MVBs is a regulatory step designed to terminate the
EGFR signal more effectively and at a prelysosomal stage
in the pathway.
 
Results
 
The effects of wortmannin on delivery of activated 
EGFRs to the lysosome
 
We identified lysosomes by incubating cells with a pulse of
HRP followed by a 2–4 h chase. As previously described
(Futter et al., 1996), in HEp-2 cells this protocol labels only
lysosomes. After loading lysosomes with HRP, cells were in-
cubated at 20
 
 
 
C with anti-EGFR antibody conjugated to
colloidal gold, which in the presence of EGF follows the
normal trafficking route of the EGFR. At 20
 
 
 
C, EGFRs are
retained in the transferrin-containing endosome, but upon
transfer to 37
 
 
 
C activated EGFRs move into the HRP-
loaded lysosome, and after 1 h at 37
 
 
 
C the majority of anti-
EGFR gold particles are in the lysosome (Fig. 1 a). When
wortmannin is included in the 37
 
 
 
C incubation, most
MVBs (defined by the presence of anti-EGFR gold but the
absence of HRP) and some lysosomes (defined by the pres-
ence of HRP) become enlarged (Fig. 1, b and c). Both
MVBs and lysosomes have fewer internal vesicles and inter-
nal membranes, but it is clear that many of the anti-EGFR
gold particles reach HRP-loaded lysosomes in the presence
of wortmannin. Counting the number of anti-EGFR gold
particles that reached HRP-filled lysosomes after 1 h at 37
 
 
 
C
showed that delivery of EGFRs to the lysosome was only
slightly inhibited (6%) by wortmannin treatment and that
the majority of EGFRs (81.9%) reached the lysosome in the
presence of wortmannin (Table I). In these experiments,
cells were allowed to take up EGFRs at 20
 
 
 
C in the absence
of wortmannin (to eliminate possible effects of wortmannin
on internalization of EGFRs), and wortmannin was only in-
cluded in the 37
 
 
 
C incubation. PI(3)P is likely to be de-
pleted rapidly from cells after wortmannin addition, since
the PI(3)P binding protein, EEA1, was released from endo-
somal membranes within 2 min of wortmannin addition at
37
 
 
 
C (unpublished data). However, to eliminate the possi-
bility that some EGFRs reached the HRP-filled lysosomes
before depletion of PI(3)P cells were preincubated with
wortmannin at 37
 
 
 
C for 30 min before loading with anti-
EGFR–gold/EGF at 20
 
 
 
C and chase at 37
 
 
 
C, all in the con-
tinued presence of wortmannin. Under these conditions,
there was a 12% reduction in the number of EGFRs reach-
ing the lysosome, but the majority (76.7%) of EGFRs still
reached the HRP-filled lysosome.
To further investigate the efficiency of delivery of EGF
and EGFRs to the lysosome in the presence of wortmannin,
the effects of wortmannin on 
 
125
 
I-EGF degradation and
 
Table I. 
 
The effects of wortmannin treatment on delivery of EGFRs to HRP-loaded lysosomes
Number of anti-EGFR gold particles 
Treatment HRP –ve vacuoles HRP +ve vacuoles Percentage of anti-EGFR gold in HRP +ve vacuoles
 
 
 
Wo 157 1,084 87.3
 
 
 
Wo 254  1,147 81.9
 
 
 
Wo 
 
 
 
 pretreatment 327  1,078  76.7
HEp-2 cells were incubated with HRP for 30 min at 37
 
 
 
C, chased for 3 h at 37
 
 
 
C, and then incubated with anti-EGFR gold and EGF for 1 h at 20
 
 
 
C, all in
the absence of wortmannin. Cells were then chased for 1 h at 37
 
 
 
C in the absence (
 
 
 
Wo) or presence of wortmannin (
 
 
 
Wo). A third group of cells was
incubated as above except that wortmannin was added for 30 min at 37
 
 
 
C before addition of anti-EGFR gold, and EGF was included in the 20
 
 
 
C incubation
and the 37
 
 
 
C chase (
 
 
 
Wo 
 
 
 
 pretreatment). The number of anti-EGFR gold particles in HRP 
 
 
 
ve vacuoles (MVBs) and HRP 
 
 
 
ve vacuoles (lysosomes) was
counted in random thin sections, and the percentage of anti-EGFR gold particles in HRP 
 
 
 
ve lysosomes was determined. 
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EGFR degradation were determined. In HEp-2 cells, 
 
 
 
70%
of endocytosed 
 
125
 
I-EGF is delivered to the lysosome and de-
graded to TCA soluble radioactivity, and 20% is released
into the extracellular medium intact (Fig. 2 a). Wortmannin
treatment had very little effect on the magnitude or kinetics
of EGF degradation, although EGF recycling was inhibited.
We have shown previously that MVB–lysosome fusion is re-
quired for EGF degradation to TCA-soluble products (Fut-
ter et al., 1996), and so these data together with the EM data
described above indicate that wortmannin treatment does
not inhibit MVB–lysosome fusion. EGFRs are normally de-
livered to the lysosome primarily on internal vesicles after
MVB–lysosome fusion. In the presence of wortmannin, a
considerable proportion of EGFRs are delivered to the lyso-
some on the perimeter membrane, and so EGF and the lu-
menal domain of the EGFR are exposed to a degradative en-
vironment, whereas the COOH terminus of the receptor
remains exposed to the cytoplasm. Therefore, we deter-
mined the rate of degradation of the EGFR in the presence
and absence of wortmannin by Western blotting with an an-
tibody against the cytoplasmic domain of the EGFR. Al-
though the rate of EGFR degradation was reduced in wort-
mannin-treated cells (Fig. 2 b), no fragments of the EGFR
indicative of partial degradation were observed.
 
The effects of wortmannin on inward vesiculation in 
cells where lysosomes have been cross-linked
 
Incubation of living cells with DAB/H
 
2
 
O
 
2
 
 crosslinks HRP-
loaded lysosomes, preventing fusion between MVBs and ly-
sosomes, and causes MVBs to accumulate (Futter et al.,
1996). This technique allows the development of the MVB
to be followed in the absence of endosome–lysosome fusion
and is particularly useful for studying inward vesiculation.
To quantify the effects of wortmannin on inward vesicula-
tion, HRP-loaded lysosomes were cross-linked and cells
were then incubated with anti-EGFR gold and EGF at 20
 
 
 
C
followed by a 1 h chase at 37
 
 
 
C in the presence or absence of
wortmannin. As shown in Fig. 3 a, in the absence of wort-
mannin MVBs with many internal vesicles accumulate, and
the EGFR gold is primarily on the internal vesicles. In the
presence of wortmannin enlarged anti-EGFR, gold-contain-
ing vacuoles accumulate (Fig. 3, b and c). These vacuoles
contain very few internal vesicles, and the majority of the
gold-labeled EGFRs is on the perimeter membrane. These
EGFRs are not evenly distributed on the perimeter mem-
brane but are clustered, and where an internal vesicle does
form it is usually labeled with anti-EGFR gold (Fig. 3 b).
The major change in volume of MVBs induced by wort-
mannin treatment may alter the probability of sectioning
through internal vesicles in any given thin section. To accu-
rately quantitate the number of internal vesicles per MVB,
we therefore analyzed serial sections to reconstruct individ-
ual MVBs in their entirety. As shown in Table II, MVBs
formed in the presence of wortmannin have fivefold fewer
internal vesicles than those formed in the absence of wort-
mannin and have approximately twice the diameter. As
shown in Fig. 4, the number of internal vesicles per MVB is
extremely variable, particularly in control cells, but the ma-
jority of MVBs have 10–40 internal vesicles per MVB. In
contrast, in wortmannin-treated cells the majority of MVBs
have less than five internal vesicles. Estimating the total
membrane area of the MVB, assuming all internal vesicles to
have a diameter of 50 nm, indicates that wortmannin-
treated vacuoles have approximately twice as much mem-
brane as control cells (Table II), suggesting that the vacuolar
enlargement cannot be explained solely by a failure to in-
wardly vesiculate. Inhibition of exit from the MVB as has
been suggested by others (Reaves et al., 1996; Kundra and
Kornfeld, 1998) may, therefore, also contribute to the vacu-
olar enlargement. MVBs allowed to accumulate for 1 h in
the presence of wortmannin have up to 50% fewer gold par-
ticles than those that accumulate in the absence of wortman-
nin. We can assume that the entry of EGFRs into the MVBs
is not inhibited by wortmannin, since in cells where the ly-
sosomes have not been cross-linked EGFRs are efficiently
Figure 2. The effects of wortmannin on EGF and EGFR degradation. 
(a) Cells were incubated with 
125I-EGF for 1 h at 20 C, surface 
stripped, and chased at 37 C in the absence or presence of wortmannin 
(wo) for up to 2 h. Media samples were TCA precipitated to determine 
the percentage of degradation. (b) Cells were incubated with EGF 
for 1 h at 20 C and then chased at 37 C for up to 2 h in the absence 
or presence of wortmannin (wo). Cell lysates were analyzed by 
SDS-PAGE followed by Western blotting with an antibody against 
the cytoplasmic domain of the EGFR. Percentage degradation is 
calculated by comparison with the amount of EGFRs in cells not 
treated with EGF. 
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Figure 3. The effects of wortmannin on inward vesiculation in cells where the lysosomes have been cross-linked. HEp-2 cells were 
incubated with HRP for 30 min at 37 C, chased for 3 h at 37 C, and then incubated with DAB/H2O2 at 4 C to crosslink the lysosomes. 
Cells were then incubated with anti-EGFR gold and EGF at 20 C in the absence of wortmannin and then chased at 37 C in the absence 
(a) or the presence of wortmannin (b and c). Note that in the absence of wortmannin, MVBs with many internal vesicles and anti-EGFR 
gold predominantly on the internal vesicles accumulate (asterisks). In the presence of wortmannin, enlarged MVBs with very few internal 
vesicles accumulate (crosses), and the EGFR are clustered (arrowheads) on the perimeter membrane of the enlarged MVBs. L, lysosome. 
Bars: (a and b) 0.1  m; (c) 0.5  m. 
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delivered to the lysosome (see above). Therefore, it is likely
that some loss of EGFRs from the perimeter membrane of
the MVB does occur in wortmannin-treated cells when
MVB–lysosome fusion is prevented.
To determine whether there is a general inhibition of exit
from MVBs in wortmannin-treated cells or whether EGFRs
are specifically retained on the perimeter membrane of
MVBs, we determined the effect of wortmannin treatment
on removal of TRs from MVBs. Lysosomes were cross-
linked in the living cell as described above. Cells were then
incubated with anti-EGFR gold and EGF at 20
 
 
 
C in the ab-
sence of wortmannin to allow EGFR internalization but re-
tain EGFRs in the TR-containing endosome. Cells were
then chased for 1 h at 37
 
 
 
C in the presence or absence of
wortmannin. In the absence of wortmannin, TRs would be
expected to be gradually removed from the maturing MVBs.
Cells were then permeabilized and immunogold labeled us-
ing an antibody to the cytoplasmic domain of the TR as de-
scribed in Materials and methods. As expected, mature
MVBs accumulated in the absence of wortmannin for 1 h at
37
 
 
 
C have very few TRs compared with surrounding vesicles
and tubules (Fig. 5, a and b). In wortmannin-treated cells,
although the MVBs are enlarged, there are also very few TRs
on the perimeter membrane compared with surrounding
vesicles and tubules (Fig. 5, b and c). Examining a single
time point does not allow the effect of wortmannin on the
rate of removal of TRs from the MVBs to be determined.
However, counting the number of EGFR- and TR-gold par-
ticles in random thin sections shows that the ratio of EGFRs
to TRs in MVBs accumulated in the presence of wortman-
nin compared with untreated cells is almost identical: 57:2
EGFRs to TRs in the absence of wortmannin and 51:2 in
the presence of wortmannin (
 
n
 
 
 
  
 
100). Thus, although in-
ward vesiculation is inhibited sorting of EGFRs from TRs
continues.
 
The effects of microinjection of anti–PI 3
 
 
 
-kinase 
antibodies on inward vesiculation
 
To determine which PI 3
 
 
 
-kinase is involved in inward
vesiculation, isotype-specific inhibitory antibodies to the
p110
 
 
 
 and p110
 
 
 
 subunits of the type 1 kinases and to
hVPS 34 (the type III kinase) were assessed for their effects
on inward vesiculation. These antibodies have been shown
to inhibit the respective PI 3
 
 
 
-kinase activities when micro-
injected into cells (Siddhanta et al., 1998). HRP-loaded ly-
sosomes were cross-linked in the living cell, and then cells
were microinjected with anti–PI 3
 
 
 
-kinase antibody and
with 20 nm gold in order to locate the microinjected cells.
Cells were then allowed to recover for a further 2 h at 37
 
 
 
C
before incubation with anti-EGFR gold and EGF at 20
 
 
 
C.
Cells were then chased at 37
 
 
 
C for 1 h before processing for
EM. Control experiments were performed to confirm that
the morphology of the cells, and the formation of MVBs was
not affected by microinjection with 20 nm gold. The micro-
injected 20 nm gold was distributed frequently throughout
the cytoplasm as single particles, although occasionally clus-
ters of gold were observed in the cytoplasm or enclosed
within a limiting membrane (Fig. 6 a). Microinjection of
anti-p110
 
 
 
 antibody did not affect the morphology of the
MVB at any dose of antibody (Fig. 6 c). Microinjection of
anti-p110
 
 
 
 antibody did not appear to affect the morphol-
ogy of the MVB at low doses. However, cells injected with
larger doses of antibody had unusually small MVBs with
very few internal vesicles, and EGFRs were often found in
small vesicles and tubules rather than MVBs (Fig. 6 d). This
suggests that p110
 
 
 
 is involved in early events in endocytic
processing and may be involved in the delivery of membrane
to the MVB. In cells microinjected with anti-hVPS34
MVBs had a reduced number of internal vesicles and the
Figure 4. The effects of wortmannin on the number of internal 
vesicles per MVB. HEp-2 cells were incubated with HRP for 30 min 
at 37 C, chased for 3 h at 37 C, and then incubated with DAB/H2O2 
at 4 C to crosslink the lysosomes. Cells were then incubated with 
anti-EGFR gold and EGF at 20 C in the absence of wortmannin and 
then chased at 37 C in the absence or the presence of wortmannin. 
The total number of internal vesicles in 13 MVBs per treatment was 
estimated by analysis of 70-nm serial sections.
 
Table II. 
 
The effects of wortmannin on inward vesiculation and membrane area per MVB
Membrane area
Treatment MVB diameter Number of internal vesicles per MVB Perimeter Internal vesicle Total
 
nm
 
 
 
m
 
2
 
 
 
Wo  386  33.8  468.1  265.5  733.6
 
 
 
Wo  698  6.3  1,530 49.5  1579.5
HEp-2 cells were incubated with HRP for 30 min at 37
 
 
 
C, chased for 3 h at 37
 
 
 
C, and then incubated with DAB/H2O2 at 4
 
 
 
C to crosslink the lysosomes.
Cells were then incubated with anti-EGFR gold and EGF at 20 C in the absence of wortmannin and then chased at 37 C in the absence ( Wo) or the presence
of wortmannin ( Wo). The total number of internal vesicles in individual MVBs was counted in serial 70-nm sections. The largest measured diameter of
each MVB was assumed to be the diameter of the vacuole. Membrane areas were calculated assuming internal vesicles to have a diameter of 50 nm. 13
MVBs were measured for each treatment.Human VPS34 and multivesicular endosomes | Futter et al. 1257
EGFRs were primarily on the perimeter membrane (Fig. 6
b). Although in some cases these MVBs were enlarged, they
were not as large as those induced by treatment with wort-
mannin. It is possible that this difference in the results of
anti–PI 3 -kinase antibody injection and wortmannin treat-
ment could be explained by differences in the timing of PI
3 -kinase inhibition. Anti–PI 3 -kinase antibodies were in-
Figure 5. The effects of wortmannin on traffic of EGFRs and TRs 
through MVBs. HEp-2 cells were incubated with HRP for 30 min at 
37 C, chased for 3 h at 37 C, and then incubated with DAB/H2O2 at 
4 C to crosslink the lysosomes. Cells were then incubated with 
anti-EGFR gold (10 nm) and EGF for 1 h at 20 C in the absence of 
wortmannin and were then chased at 37 C for 1 h in the absence 
(a and b) or the presence of wortmannin (c). Cells were then perme-
abilized, fixed, and labeled with anti-TR antibody (5 nm gold). Note 
that in both the absence and the presence of wortmannin there are 
very few TRs on MVBs, but small vesicles labeling strongly for TRs 
(arrows) are often in close proximity. Bars, 0.1  m.
Figure 6. The effects of microinjection with anti–PI 3 -kinase 
antibodies on inward vesiculation in cells where the lysosomes 
have been cross-linked. HEp-2 cells were incubated with HRP for 
30 min at 37 C, chased for 3 h at 37 C, and then incubated with 
DAB/H2O2 at 4 C to crosslink the lysosomes. Cells were then 
microinjected at 37 C with 20 nm BSA gold (arrows) alone (a) or 
coinjected with anti-hVPS34 antibody (b), anti-p110  antibody (c), 
or anti-p110  antibody (d). Cells were then incubated with 10 nm 
anti-EGFR gold (arrowheads) and EGF for 1 h at 20 C and were then 
chased at 37 C for 1 h. Microinjection with the anti-hVPS34 anti-
body caused the generation of enlarged MVBs containing few inter-
nal vesicles (asterisks). Microinjection with anti-p110  had no effect 
on MVB formation, whereas microinjection with p110  in some 
cases caused the generation of MVBs with comparatively few
EGFRs, but they were not enlarged. Bars, 0.5  m.1258 The Journal of Cell Biology | Volume 155, Number 7, 2001
jected before the addition of anti-EGFR gold and EGF,
whereas wortmannin was added to the cells after they had
been incubated with anti-EGFR gold and EGF at 20 C.
Therefore, we performed further microinjection experi-
ments to mimic the experiments using wortmannin as
closely as possible. HRP-loaded lysosomes were cross-linked
in the living cell, and then cells were loaded with anti-EGFR
gold and EGF at 20 C. Cells were then microinjected with
antibody and with 20 nm gold particles and were then incu-
bated for a further 30 min at 20 C to allow time for the mi-
croinjected antibody to bind its antigen within the cell. Cells
were then chased at 37 C for 1 h. Microinjection of the anti-
hVPS34 antibody caused the formation of enlarged MVBs
with very few internal vesicles and with EGFRs on the pe-
rimeter membrane, closely mimicking the effects seen with
wortmannin treatment (Fig. 7 a). This effect appeared to be
dose dependent. In cells with large amounts of injected 20
nm gold (indicating a larger volume of microinjected anti–
PI 3 -kinase antibody), MVBs were large and had very few
internal vesicles. Cells containing fewer injected gold parti-
cles seemed to have smaller MVBs with a few internal vesi-
cles but still contained fewer internal vesicles than MVBs of
control cells (unpublished data). Therefore, we conclude
that the inhibition of inward vesiculation within the MVB
by wortmannin is due to inhibition of the PI 3 -kinase
hVPS34. Large doses of anti-p110  antibody sometimes led
to a decrease in the size of MVBs and some accumulation of
EGFRs in small vesicles and tubules (Fig. 7 b). This is an ef-
fect not observed with wortmannin treatment. p110  may
be involved in an early step in the maturation of MVBs and
is presumably more effectively inhibited by microinjection
than by wortmannin treatment.
The effects of wortmannin on EGF-stimulated tyrosine 
phosphorylation
The above data suggests that EGFRs carry information that
allows them to be retained on the perimeter membrane of
MVB while TRs are being removed from this location to the
recycling pathway, and that retention of EGFRs on the pe-
rimeter membrane is sufficient to target them for lysosomal
delivery. This raises the question of the purpose of inward
vesiculation. One possible purpose could be the removal of
EGFRs from exposure to the cytoplasmic matrix and hence
from substrates for their kinase activity. Therefore, we deter-
mined the effects of inhibition of inward vesiculation on the
spectrum of proteins phosphorylated by the EGFR kinase.
To enhance potential differences, lysosomes were cross-
linked to prevent EGFR degradation, and then cells were in-
cubated with EGF at 20 C followed by chase at 37 C in the
presence or absence of wortmannin. MVBs with EGFRs on
the perimeter membrane and exposed to the cytoplasm (in
the presence of wortmannin) could be compared with
MVBs with EGFRs on internal vesicles sequestered from the
cytoplasm (in the absence of wortmannin). Tyrosine-phos-
phorylated proteins were detected by Western blotting cell
lysates with antiphosphotyrosine antibody. As shown in Fig.
8, the pattern and strength of phosphorylation is increased
significantly in wortmannin-treated cells. Since there is some
loss of EGFRs from the perimeter membrane of MVBs in
Figure 7. The effects of microinjection with anti–PI 3 -kinase 
antibodies after incubation with EGF at 20 C. HEp-2 cells were 
incubated with HRP for 30 min at 37 C, chased for 3 h at 37 C, 
and then incubated with DAB/H2O2 at 4 C to crosslink the 
lysosomes. Cells were then incubated with 10 nm anti-EGFR 
gold (arrowheads) and EGF for 1 h at 20 C and were then 
microinjected with 20 nm BSA gold (arrows) and anti-hVPS34 (a) 
or anti-p110  (b) at 20 C before incubation at 20 C for a further 
30 min and then chase at 37 C for 1 h. Microinjection of 
anti-hVPS34 caused the generation of enlarged MVBs with very 
few internal vesicles and EGFRs on the perimeter membrane. 
Microinjection of anti-p110  antibody caused the formation 
of small MVBs with few internal vesicles and few EGFRs. 
Bars, 0.2  m.Human VPS34 and multivesicular endosomes | Futter et al. 1259
wortmannin-treated cells in which the lysosomes have been
cross-linked, we cannot be sure that all the tyrosine-phos-
phorylated proteins are on the perimeter membrane of
MVBs in wortmannin-treated cells. However, these data
are consistent with the possibility that inward vesiculation
within MVBs removes EGFRs from potential cytoplasmic
substrates.
Discussion
Wortmannin treatment has multiple effects on both endo-
and exocytic pathways, including the stimulation of clath-
rin-dependent endocytosis (Martys et al., 1996; Spiro et al.,
1996), the inhibition of endosome–endosome fusion in
vitro (Jones and Clague, 1995; Li et al., 1995; Spiro et al.,
1996), the inhibition of TR recycling (Martys et al., 1996;
Shpetner et al., 1996; Spiro et al., 1996), the formation of
enlarged late endosomes (Reaves et al., 1996; Bright et al.,
1997; Kundra and Kornfeld, 1998; Fernandez-Borja et al.,
1999), and inhibition of the perinuclear clustering and deg-
radation of platelet-derived growth factor receptors (PD-
GFRs) (Joly et al., 1995; Shpetner et al., 1996). We have ex-
amined the effects of wortmannin on the endocytic pathway
followed by activated EGFRs en route to the lysosome.
Wortmannin treatment inhibits inward vesiculation 
within MVBs but not EGFR delivery to the lysosome
In common with others, we find that wortmannin treatment
causes the formation of enlarged endocytic vacuoles. After
1 h at 37 C, there is a minor enlargement of lysosomes, but
the enlargement of vacuoles, recognizable as MVBs because
they lack dense content and usually contain one or more
small vesicles, is more marked. The enlarged MVBs fre-
quently have comparatively few internal vesicles, and the
EGFRs are found more frequently on the perimeter mem-
brane compared with cells not treated with wortmannin.
Wortmannin-induced enlargement of late endosomes and
lysosomes has been proposed to be due to an inhibition of
exit of proteins like mannose 6-phosphate receptor from
these structures (Kundra and Kornfeld, 1998), an inhibition
of reformation of lysosomes after endosome–lysosome fu-
sion (Bright et al., 1997), or an inhibition of inward vesicu-
lation (Fernandez-Borja et al., 1999). In the latter study on a
human melanoma cell line, the authors found that wort-
mannin treatment generated enlarged vacuoles with few in-
ternal vesicles and proposed that wortmannin inhibited the
invagination and/or pinching off of intraluminal vesicles of
both MHC class II compartments and of other components
of the endocytic pathway. A recent study from Bright et al.
(2001) found that prolonged wortmannin treatment of
NRK fibroblasts did not prevent the accumulation of inter-
nal vesicles within enlarged endocytic vacuoles and con-
cluded that vacuolar enlargement was due to inhibition of
exit of membrane from these structures.
We have developed a technique that allows the matura-
tion of MVBs to be followed in the absence of MVB–lyso-
some fusion (Futter et al., 1996). By preincubation of
HRP-loaded lysosomes with DAB/H2O2, which cross-links
the lysosome in the living cell, MVB–lysosome fusion is
prevented, but maturation of the MVB, in which inward ve-
siculation transfers EGFRs to the inner vesicle, proceeds. By
including wortmannin in this protocol, we have demon-
strated that there is a fivefold reduction in the accumulation
of internal vesicles within the MVB and that EGFRs remain
primarily on the perimeter membrane. Estimating the
amount of membrane per MVB suggests that vacuolar en-
largement cannot be explained solely by an inhibition of in-
ward vesiculation. Therefore, it is likely that both inhibition
of inward vesiculation and inhibition of exit of proteins,
such as MPR, from the MVB contributes to the vacuolar en-
largement. However, wortmannin-induced inhibition of exit
from MVBs is selective, since TRs are efficiently removed
from the maturing MVBs. This observation needs to be rec-
onciled with several published studies which have reported
that wortmannin treatment inhibits TR recycling (Martys et
al., 1996; Shpetner et al., 1996; Spiro et al., 1996) and our
finding that wortmannin inhibits the recycling of the small
proportion of internalized EGF that is normally recycled.
EM demonstrates that the majority of TRs in wortmannin-
treated cells is in endosomal tubules, a compartment which
is expanded in these cells (unpublished data; Shpetner et al.,
1996) rather than in MVBs. Therefore, it is probable that it
is within tubules rather than in MVBs that the trafficking of
these recycling receptors is being inhibited.
Despite the inhibition of inward vesiculation, EGFRs are
still delivered to the lysosome in the presence of wortman-
nin, and EGF degradation is largely unaffected. Although
some proteolytic processing of EGF has been reported to oc-
cur in prelysosomal compartments (Schaudies et al., 1987;
Renfrew and Hubbard, 1991), we have shown previously
that MVB–lysosome fusion is required for the degradation
of EGF to TCA-soluble products (Futter et al., 1996).
Therefore, we conclude that MVB–lysosome fusion is not
affected by wortmannin treatment. The EGFR is degraded
with slower kinetics in wortmannin-treated cells. Similarly,
the rate but not extent of degradation of Semliki Forest virus
was found to be reduced by wortmannin treatment (Martys
et al., 1996). We have been unable to detect degradation
products of the EGFR indicative of partial degradation of
the receptor, suggesting that the EGFR is unstable in the pe-
rimeter membrane of the lysosome. There is no indication
in our studies of the means whereby the cytoplasmic domain
of the EGFR is degraded in wortmannin-treated cells. Previ-
ous studies would support the notion that MVB–lysosome
fusion can occur in the presence of wortmannin, since
Figure 8. The effects of wortmannin on 
EGF-stimulated tyrosine phosphorylation 
in cells were the lysosomes have been 
cross-linked. HEp-2 cells were incubated 
with HRP for 30 min at 37 C, chased for 
3 h at 37 C, and then incubated with 
DAB/H2O2 at 4 C to crosslink the lyso-
somes. Cells were then incubated in the 
presence or absence of EGF at 20 C for
1 h and then chased at 37 C in the pres-
ence or absence of wortmannin (wo). 
Cell lysates were analyzed by SDS-
PAGE followed by Western blotting 
with antiphosphotyrosine antibody.1260 The Journal of Cell Biology | Volume 155, Number 7, 2001
Bright et al. (1997) identified lysosomes with a pulse of BSA
gold and showed that a second pulse of BSA gold could
reach the previously internalized gold even in the presence of
wortmannin. These authors have shown that endosome–
lysosome fusion results in the generation of a hybrid com-
partment from which dense core lysosomes must be re-
formed (Mullock et al., 1998). Wortmannin treatment
reduced the number of dense core lysosomes within the cell,
suggesting an inhibition of the reformation of dense lyso-
somes (Bright et al., 1997).
The delivery of PDGFRs to the lysosome has been re-
ported to be inhibited by wortmannin (Joly et al., 1995;
Shpetner et al., 1996). In the latter study, fluid phase mark-
ers could reach the lysosome in the presence of wortmannin,
again indicating that wortmannin did not prevent endo-
some–lysosome fusion but rather that wortmannin inhibited
the targetting of PDGFRs to that pathway. In contrast, we
found that wortmannin treatment did not affect the target-
ting of EGFRs to the lysosomal pathway. We have proposed
previously that movement of EGFRs onto the internal vesi-
cles of MVBs is critical for removing EGFRs from the recy-
cling pathway and targetting them to the lysosome. Inactiva-
tion of the tyrosine kinase activity of the EGFR inhibited
movement of the EGFR onto the internal vesicles of MVB
and, in this case, the EGFR recycled (Felder et al., 1990). In
wortmannin-treated cells, the movement of the EGFR onto
the internal vesicles is also inhibited, but in this case the
EGFR is not recycled; it is delivered to the lysosome and de-
graded. Taken together, these results suggest that we have
resolved two stages in the inward vesiculation process: (a) se-
lection of EGFRs for inclusion in the internal vesicle, which
requires tyrosine kinase activity but not PI 3 -kinase activity
and is represented by the clusters of EGFRs on the perim-
eter membrane of MVBs in wortmannin-treated cells and
(b) vesicle formation, which requires PI 3 -kinase activity.
EGFR tyrosine kinase activity but not PI 3 -kinase activity
is, therefore, necessary to retain the EGFR in the MVB and
prevent recycling.
The fact that wortmannin treatment inhibits lysosomal
targeting of PDGFRs (Shpetner et al., 1996) but not EGFRs
(this study) could be because lysosomal targeting of PD-
GFRs and EGFRs are regulated differently. Alternatively, in
our experiments wortmannin was only added after EGFRs
had been internalized at 20 C, and so it is possible that a PI
3 -kinase is involved in an early step in the processing of
EGFRs proximal to the 20 C block. Consistent with this
possibility is our finding that when cells were treated with
wortmannin before addition of EGF, there was a small re-
duction in the number of EGFRs reaching the lysosome,
and also when anti-PI 3 -kinase antibodies were microin-
jected before addition of EGF, delivery of EGFRs to MVBs
was, in some cases, partially inhibited (see below).
hVPS34 is the PI 3-kinase required for
inward vesiculation
There are three classes of mammalian PI 3 -kinases, which
differ both in their regulation and their substrate specificities
(Rameh and Cantley, 1999). Class I and class III PI 3 -
kinases have distinct roles in endocytic traffic. Microinjec-
tion of inhibitory anti-p110  antibody inhibits TR recycling,
whereas microinjection of anti-hVPS34 but not anti-p110 
inhibits transit of internalized PDGFRs to a perinuclear
compartment (Siddhanta et al., 1998). Here, we show that
microinjection with inhibitory anti-hVPS34 but not anti-
p110  or anti-p110   causes the generation of enlarged
MVBs. These MVBs contain reduced numbers of internal
vesicles, and EGFRs remain on the perimeter membrane.
Therefore, we conclude that hVPS34 is the PI 3 -kinase re-
quired for inward vesiculation within MVBs. Some reduc-
tion in size of MVBs was observed in cells microinjected
with anti-p110  (and hVPS34 when microinjected before
the addition of EGF), suggesting a possible role of these PI
3 kinases in an early step in the sorting of EGFRs, which
would be consistent with their recruitment by rab5 to early
endosomes (Christoforidis et al., 1999). PDGFR mutants
that fail to bind PI 3 -kinases are unable to enter the lysoso-
mal pathway, suggesting a role of the class I PI 3 -kinases in
this effect (Joly et al., 1995). On the other hand, microinjec-
tion of anti-hVPS34 inhibited accumulation of PDGFRs in
the perinuclear area, indicating a role for this PI 3 -kinase in
sorting of PDGFRs (Siddhanta et al., 1998). It is not possi-
ble to determine the roles of PI 3 -kinases in early events in
the sorting of EGFRs from the results of our experiments,
but both p110  and hVPS34 may have roles in addition to
that demonstrated here for hVPS34 in inward vesiculation.
The product of hVPS34, PI(3)P, is specifically recognized
by proteins containing a cysteine-rich zinc finger domain,
termed the FYVE domain. FYVE domains are found in sev-
eral proteins implicated in membrane trafficking, including
EEA1, Fab1, Vac1, Hrs (Stenmark and Aasland, 1999), and
rabenosyn 5 (Nielsen et al., 2000). Association of EEA1 and
rabenosyn 5 with endosomes involves binding to both
PI(3)P and rab5-GTP (Patki et al., 1998; Simonsen et al.,
1998; Nielsen et al., 2000). EEA1 is required for endosome–
endosome fusion in vitro (Mills et al., 1998; Simonsen et al.,
1998) and may act as a tethering factor (Pfeffer, 1999), me-
diating endosome–endosome docking (Christoforidis et al.,
1999). Fab1 is a PI(3)P 5-kinase and therefore phosphory-
lates the product of VPS34. Mutations in yeast Fab1 cause
expansion of the vacuole and retention of carboxypeptidase
S, which is normally degraded within the lumen of the vacu-
ole, on the perimeter membrane (Odorizzi et al., 1998).
This shows a striking similarity with the phenotype observed
for EGFRs in wortmannin-treated cells. Hrs has been local-
ized to endosomes (Komada et al., 1997) where it can recruit
clathrin (Raiborg et al., 2001), becomes tyrosine phosphory-
lated in response to several growth factors, including EGF,
(Komada and Kitamura, 1995; Komada et al., 1997), and
tyrosine phosphorylation causes the release of Hrs from en-
docytic vacuoles (Urbe et al., 2000). In addition to the
FYVE domain, the PX domain contained in SNX3 has been
shown recently to bind PI(3)P, and this domain is found in
a family of proteins termed SNXs (Xu et al., 2001). SNX1
binds to the EGFR and can also interact with Hrs (Chin et
al., 2001). Overexpression of SNX1 enhances EGFR degra-
dation (Kurten et al., 1996), whereas overexpression of Hrs
or the SNX1 binding domain of Hrs inhibits EGFR degra-
dation, suggesting that Hrs may regulate the traffic of
EGFRs through SNX1 (Komada and Soriano, 1999; Chin
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domains which specifically recognize PI(3)P. Some of these
proteins have been implicated in the regulation of the traffic
of the EGFRs, but as yet no role of any of these proteins in
either selection of cargo for inclusion in internal vesicles or
in vesicle formation has been demonstrated directly. Our
data suggest that the generation of PI(3)P-rich domains on
the perimeter membrane of the MVB is required for vesicle
formation but not for lysosomal targetting of EGFRs. Given
that Hrs and SNX1 have been implicated in lysosomal tar-
getting of the EGFR, it is possible that these proteins play a
role at an early step in the sorting of endocytosed EGFRs be-
fore the generation of internal vesicles within MVBs and
that other PI(3)P binding proteins, such as Fab1, are re-
quired for inward vesiculation.
The generation of PI(3)P-rich domains on the perimeter
membrane of the MVB requires the localization of hVPS34
to that domain. hVPS34 localization within the endosomal
membrane may be regulated by rab5, since rab5 is localized
to the endosomal membrane and hVPS34 interacts indi-
rectly with activated rab5 (Christoforidis et al., 1999). Un-
like the class I PI 3 -kinases, hVPS34 has not been shown to
be regulated directly by growth factors. However, EGFR ac-
tivation has been shown recently to induce activation of
rab5a (Barbieri et al., 2000), and so EGF stimulation of rab5
may play a role in the localization of hVPS34. A recent
study localizing PI(3)P at the light and EM level found this
lipid to be highly enriched on early endosomes and on the
internal vesicles of MVBs (Gillooly et al., 2000). This would
be in keeping with the generation of patches of PI(3)P on
the perimeter membrane, leading to inward vesiculation.
Yeast studies suggest that PI(3)P must be transported to the
vacuole/lysosome for turnover (Wurmser and Emr, 1998),
and so PI(3)P would be expected to remain on the internal
vesicles of MVBs until MVB–lysosome fusion.
Taken together, a model emerges whereby the rab5-
dependent recruitment of hVPS34 results in the generation
of microdomains rich in PI(3)P that recruit effector pro-
teins, leading to inward vesiculation.
Sequestration of activated EGFRs within the lumen of 
MVBs removes the receptor from potential 
phosphotyrosine substrates
Retention on the perimeter membrane of MVBs is sufficient
for the lysosomal targetting and degradation of activated
EGFRs, raising the question of the purpose of the inward ve-
siculation process. Several studies suggest that EGFRs can
continue to signal while they remain on the perimeter mem-
branes of the endocytic pathway. Thus, it has been shown that
EGFRs remain phosphorylated in the endosome (Wada et al.,
1992) but become inactivated before degradation (Burke et
al., 2001). Although some substrates of the EGFR kinase are
phosphorylated on the plasma membrane, others, such as an-
nexin 1 (Futter et al., 1993) and Eps8 (Burke et al., 2001), ap-
pear to be phosphorylated by the endosomal but not the
plasma membrane EGFR kinase. Inhibition of endocytosis of
EGFRs by expression of mutant dynamin inhibits Erk1/2
MAP kinase signaling (Vieira et al., 1996) and Erk2 activation
can be initiated from the endosomal EGFR kinase in a cell-
free system (Xue and Lucocq, 1998). Activated Raf-1 and
Mek have been localized to endosomes after EGF stimulation
(Pol et al., 1998). Therefore, it is likely that endocytosed
EGFRs, which continue to be exposed to the cytoplasm, con-
tinue to signal. When they become sequestered on internal
vesicles of MVBs, their access to cytosolic substrates is pre-
sumably lost. We have addressed this question directly by
comparing the activity of the EGFR kinase in cells in which
EGFRs are retained on, with those in which they are removed
from, the perimeter membrane. When EGFRs were retained
on the perimeter membrane, tyrosine phosphorylation of a
large number of proteins was enhanced, demonstrating that
there are a large number of potential substrates of the EGFR
kinase available to the cytoplasmically exposed EGFR. There-
fore, a likely purpose of inward vesiculation is to sequester
the activated EGFR away from cytoplasmic substrates and
thereby attenuate its signal transduction.
Materials and methods
Reagents
Monoclonal antibody to the extracellular domain of the EGFR (108) and
the cytoplasmic domain of the TR were gifts from J. Schlessinger (New
York University Medical Center, New York, NY) and I. Trowbridge (The
Salk Research Institute, San Diego, CA), respectively. Rabbit polyclonal
antibodies against hVPS34, p110 , and p110  were as previously de-
scribed (Siddhanta et al., 1998; Christoforidis et al., 1999). Rabbit poly-
clonal antibody against the cytoplasmic domain of the EGFR was raised by
immunization with the peptide Cys-DVVDADEYLIPQ coupled to KLH.
Monoclonal antiphosphotyrosine antibody (PY20) was from ICN Biomedi-
cals. HRP (type II) and wortmannin were from Sigma-Aldrich. Radiola-
beled EGF and colloidal gold sols were made as described previously (Slot
and Geuze, 1985; Futter et al., 1996).
Cell culture and incubation conditions
HEp-2 cells were maintained in DME containing 10% FCS in a 5% CO2 at-
mosphere. Lysosomes were loaded with HRP and cross-linked in living
cells as described in Futter et al. (1996). EGF was used at a concentration
of 200 ng/ml, and wortmannin was used at a concentration of 200 nM.
EM
For conventional EM, cells grown on glass coverslips were incubated with
HRP and gold probes under different conditions as described in the text
and were then fixed, processed, and treated with tannic acid as described
previously (Stinchcombe et al., 1995). Coverslips were embedded on Epon
stubbs, and the coverslips were then removed by immersion in liquid ni-
trogen. Cells were sectioned en face, stained with lead citrate, and viewed
in Philips 400 or CM12 electron microscopes.
For morphometry, serial 70-nm sections were cut, the diameter of the MVB
was measured, and the number of internal vesicles per MVB were counted.
An MVB was defined as a vacuole that contained anti-EGFR gold particles and
had a diameter of greater than 200 nm. The total membrane area per MVB
was estimated by assuming the diameter of internal vesicles to be 50 nm.
To quantitate the numbers of TRs and EGFRs/MVBs, lysosomes were
cross-linked and cells were incubated with anti-EGFR gold, EGF, and wort-
mannin as described above. Cells were then permeabilized and labeled
with an antibody to the cytoplasmic domain of the TR as described in Fut-
ter et al. (1998). The number of anti-EGFR gold particles and anti-TR gold
particles per MVB in random thin sections were counted.
Microinjection of anti–PI 3 -kinase antibodies
HEp-2 cells were grown on Cellocate glass-gridded coverslips (Eppendorf).
Microinjection was performed using an Eppendorf semiautomated tran-
sjection system, and the needles were pulled using a Sutter p-97 micropi-
pette puller. 1.5- l aliquots of anti-hVPS34, anti-p110 , and anti-p110 
antibodies (3–4 mg/ml in PBS) were mixed with equal volumes of BSA-sta-
bilized 20 nm gold and microinjected into the cytoplasm of cells. After
embedding in Epon, ultrathin sections were cut from the appropriate grid
area containing the microinjected cells and examined by EM.
Measurement of EGF degradation
The intracellular degradation of 
125I-EGF results in the generation of TCA-
soluble products of degradation that diffuse rapidly out of the cell and can1262 The Journal of Cell Biology | Volume 155, Number 7, 2001
be collected in the extracellular medium. After incubation of cells with
125I-EGF, the extracellular medium was collected and precipitated with
10% TCA at 4 C for 2 h. TCA precipitable proteins were pelleted by cen-
trifugation at 14,000 g at 4 C, and pellet and supernatant were counted. By
also counting the radioactivity remaining associated with the cells, the per-
centage degradation of EGF could be determined.
Measurement of EGFR degradation
After incubation of cells with EGF, cell lysates were subjected to SDS-
PAGE and Western blotted using a rabbit polyclonal antibody against the
cytoplasmic domain of the EGFR. Western blots were visualized using
ECL-Plus (Amersham Pharmacia Biotech) and quantitated using a Fuji
PhosphorImager.
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